Hydrophilic surface coatings with embedded biocidal silver nanoparticles and sodium heparin for central venous catheters

Biomaterials

Volumn 32, Issue 5, 2011, Pages 1264-1269

  Stevens, Kris N J ^a   Croes, Sander ^b   Boersma, Rinske S ^b   Stobberingh, Ellen E ^b   van der Marel, Cees ^c   van der Veen, Frederik H ^a   Knetsch, Menno L W ^a   Koole, Leo H ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c PHILIPS RESEARCH LABORATORIES   (Netherlands)

Author keywords

Catheter infection; Heparin; Platelet activation; Silver; Surface analysis; Thrombogenicity

Indexed keywords

ANTI-COAGULATION; BIFUNCTIONAL; BIOCIDAL; BIOCIDAL ACTIVITY; CLINICAL ISOLATES; CLINICAL TRIAL; CYTOSTATIC; HEMODYNAMIC PARAMETERS; HEPARIN; HYDROPHILIC SURFACES; LOW-MOLECULAR WEIGHT HEPARINS; N-BUTYL METHACRYLATE; NOVEL COATINGS; PLATELET ACTIVATION; REFERENCE STRAINS; S. AUREUS; SILVER NANOPARTICLES; STAPHYLOCOCCUS AUREUS; THROMBOGENICITY; UPPER LIMBS; VITAMIN K;

ACTIVATION ANALYSIS; CATHETERS; CHEMOTHERAPY; DIALYSIS; HEART VALVE PROSTHESES; HYDROPHILICITY; INORGANIC COATINGS; NANOPARTICLES; ORGANIC POLYMERS; PLATELETS; POLYSACCHARIDES; SODIUM; SURFACE ANALYSIS;

SILVER;

BIOCIDE; HEPARIN; METHACRYLIC ACID; N BUTYL METHACRYLATE; N VINYLPYRROLLIDINONE; SILVER NANOPARTICLE; UNCLASSIFIED DRUG; VINYL DERIVATIVE;

ADULT; AGED; ARTICLE; BACTERIAL STRAIN; BACTERIUM COLONY; BACTERIUM ISOLATE; CENTRAL VENOUS CATHETER; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; HYDROPHILICITY; MALE; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; THROMBIN TIME;

ANTI-INFECTIVE AGENTS; ANTICOAGULANTS; BACTERIAL ADHESION; CATHETERIZATION, CENTRAL VENOUS; HEPARIN; HUMANS; METAL NANOPARTICLES; METHACRYLATES; POLYMERS; PYRROLIDINONES; SILVER; THROMBOSIS;

BACTERIA (MICROORGANISMS); STAPHYLOCOCCUS AUREUS;

EID: 78649755824     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.10.042     Document Type: Article

References (25)

1. Frasca D., Dahyot-Fizelier C., Mimoz O. Prevention of central venous catheter-related infection in the intensive care unit. Crit Care 2010, 14:212-220.
2. Sabatier C., Ferrer R., Valles J. Treatment strategies for central venous catheter infections. Expert Opin Pharmacother 2009, 10:2231-2243.
3. Geffers C., Gastmeier A., Schwab F., Groneberg K., Rüden H., Gastmeier P. Use of central venous catheter and peripheral venous catheter as risk factors for nosocomial bloodstream infection in very-low-birth-weight infants. Infect Control Hosp Epidemiol 2010, 31:395-401.
4. McGee D.C., Gould M.K. Preventing complications of central venous catheterization. N Engl J Med 2003, 348:1123-1133.
5. Casey A.L., Mermel L.A., Nightingale P., Elliott T.S. Antimicrobial central venous catheters in adults: a systematic review and meta-analysis. Lancet Infect Dis 2008, 8:763-776.
6. Verso M., Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003, 21:3665-3675.
7. Khorana A.A. Cancer and thrombosis: implications of published guidelines for clinical practice. Ann Oncol 2009, 20:1619-1630.
8. Yukisawa S., Fujiwara Y., Yamamoto Y., Ueno T., Matsueda K., Kohno A., et al. Upper-extremity deep vein thrombosis related to central venous port systems implanted in cancer patients. Br J Radiol 2010, 83:850-853.
9. Couban S., Goodyear M., Burnell M., Dolan S., Wasi P., Barnes D., et al. Randomised placebo-controlled study of low-dose warfarin for the prevention of central venous catheter related thrombosis in patients with cancer. J Clin Oncol 2005, 23:4063-4069.
10. Schroeder A.R., Axelrod D.M., Silverman N.H., Rubesova E., Merkel E., Roth S.J. A continuous heparin infusion does not prevent catheter-related thrombosis in infants post cardiac surgery. Pediatr Crit Care Med 2010, 11:489-495.
11. Mermel L.A., Allon M., Bouza E., Craven D.E., Flynn P., O'Grady N.P., et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 49:1-45.
12. Stevens K.N., Crespo-Biel O., van den Bosch E.E., Dias A.A., Knetsch M.L.W., Aldenhoff Y.B.J., et al. The relationship between the antimicrobial effect of catheter coatings containing silver nanoparticles and the coagulation of contacting blood. Biomaterials 2009, 30:3682-3690.
13. Aldenhoff Y.B.J., Hanssen J.H.L., Knetsch M.L.W., Koole L.H. Thrombus formation at the surface of guide-wire models: effects of heparin-releasing or heparin-exposing surface coatings. J Vasc Interv Radiol 2007, 18:419-425.
14. Aldenhoff Y.B.J., Knetsch M.L.W., Hanssen J.H.L., Lindhout T., Wielders S.J., Koole L.H. Coils and tubes releasing heparin. Studies on a new vascular graft prototype. Biomaterials 2004, 25:3125-3133.
15. Maki D.G., Weise C.E., Sarafin H.W. A semiquantitative culture method for identifying intravenous catheter-related infection. N Engl J Med 1977, 296:1305-1309.
16. Sauer K., Steczko J., Ash S.R. Effect of a solution containing citrate/methylene blue/parabens on S. aureus bacteria and biofilm, and comparison with various heparin solutions. J Antimicrob Chemother 2009, 63:937-945.
17. Shanks R.M., Donegan N.P., Graber M.L., Buckingham S.E., Zegans M.E., Cheung A.L., et al. Heparin stimulates Staphylococcus aureus biofilm formation. Infect Immun 2005, 73:4596-4606.
18. Diskin C.J., Stokes T.J., Dansby L.M., Radcliff L., Carter T.B. Heparin and biofilm: is this the risk factor for catheter-related sepsis?. Am J Kidney Dis 2008, 52:197-198.
19. Malmsten M., Davoudi M., Schmidtchen A. Bacterial killing by heparin-binding peptides from PRELP and thrombospondin. Matrix Biol 2006, 25:294-300.
20. Andersson E., Rydengård V., Sonesson A., Mörgelin M., Björck L., Schmidtchen A. Antimicrobial activities of heparin-binding peptides. Eur J Biochem 2004, 271:1219-1226.
21. Stevens K.N., Knetsch M.L.W., Sen A., Sambhy V., Koole L.H. Disruption and activation of blood platelets in contact with an antimicrobial composite coating consisting of a pyridinium polymer and AgBr nanoparticles. ACS Appl Mater Interfaces 2009, 1:2049-2054.
22. Sambhy V., MacBride M.M., Peterson B.R., Sen A. Silver bromide nanoparticle/polymer composites: dual action tunable antimicrobial materials. J Am Chem Soc 2006, 128:9798-9808.
23. Agarwal A., Weis T.L., Schurr M.J., Faith N.G., Czuprynski C.J., McAnulty J.F., et al. Surfaces modified with nanometer-thick silver-impregnated polymeric films that kill bacteria but support growth of mammalian cells. Biomaterials 2010, 31:680-690.
24. Pijls R.T., Hanssen H.H., Nuijts R.M., Daube G.W., Koole L.H. In vivo tolerance and kinetics of a novel ocular drugh delivery device. J Control Release 2006, 116:47-49.
25. Pijls R.T., Cruijsberg L.P., Nuijts R.M., Dias A.A., Koole L.H. Capacity and tolerance of a new device for ocular drug delivery. Int J Pharm 2007, 341:152-161.